← Back

HitGen Inc. A

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; virtual screening; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company's product pipeline also includes HG146, which is in phase Ia clinical trial is a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; and HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation. In addition, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Further, the company focuses on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. The company was incorporated in 2012 and is based in Chengdu, China.

Price · split & dividend adjusted
News & notes moving 688222.CG
Biotech & Genomic Medicine3

Chengdu HitGen 2026 Interim Report: Revenue and Net Profit Both Rise, Multiple Business Segments Drive Growth Together

Chengdu HitGen released its 2026 interim report on August 26. During the reporting period, the company achieved operating revenue of 346 million yuan, up 52.41 percent year on year. Net profit attributable to the parent company was 80.68 million yuan, up 61.21 percent. Net profit after deducting non-recurring items was 76.98 million yuan, up 42.80 percent. The performance growth was mainly driven by a recovery in global demand for innovative drug research and development and strong growth across business segments. The DEL business, as the cornerstone, recorded revenue of 166 million yuan, up 62.14 percent year on year, with gross margin maintained at 77.43 percent. The OBT segment posted revenue of 54.03 million yuan, a sharp increase of 94.03 percent. The FBDD and SBDD segment led by the UK subsidiary Vernalis recorded revenue of 85.09 million yuan, up 30.43 percent. In addition, Motian Intelligence, which was consolidated as a controlling stake at the end of 2025, contributed data service revenue of 15.44 million yuan, becoming a new growth driver. The company's net cash flow from operating activities was 121 million yuan, up 9.44 percent year on year. However, affected by the appreciation of the renminbi, the company incurred exchange losses of about 14.17 million yuan during the period. Looking ahead, the company faces exchange rate fluctuation risks and goodwill impairment pressure, and needs to monitor the order conversion efficiency of the DEL and OBT segments as well as the clinical progress of proprietary pipeline projects such as HG146.
蓝鲸财经·1dRead more ▾
Biotech & Genomic Medicine

Chengdu HitGen first-half net profit attributable to parent 80.68 million yuan, up 61.2% year on year

Chengdu HitGen released its 2026 half-year report. First-half net profit attributable to the parent was 80.68 million yuan, up 61.2% year on year. Operating revenue was 346 million yuan, up 52.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 76.98 million yuan, up 42.8% year on year. Net operating cash flow was 121 million yuan, up 9.4% year on year. Earnings per share were 0.2013 yuan. In the second quarter, operating revenue was 185 million yuan, up 54.2% year on year, and net profit attributable to the parent was 39.18 million yuan, up 80.1% year on year. As of the end of the second quarter, total assets were 1.995 billion yuan, up 2.1% from the end of the previous year, and net assets attributable to the parent were 1.526 billion yuan, up 1.6%. During the reporting period, all business segments achieved growth. DEL business revenue was 166 million yuan, up 62.14% year on year. FBDD and SBDD platform revenue was 85.09 million yuan, up 30.43% year on year. OBT segment revenue was 54.03 million yuan, up 94.03% year on year. TPD segment revenue was 8.46 million yuan, up 12.25% year on year.
财中社·1dRead more ▾
688222.CG

Chengdu XianDao shareholder Shenzhen Juntian cuts 3.52 million shares, cashing out 130 million yuan

Chengdu XianDao announced that shareholder Shenzhen Juntian Investment Enterprise Limited Partnership completed a reduction of 3.52 million shares, accounting for 0.88 percent of the company's total share capital, with total reduction proceeds of 130 million yuan. After the reduction, Shenzhen Juntian still holds 6.54 million shares, representing 1.63 percent of the company's total share capital, and the reduction period disclosed in this plan has expired. In addition, Chengdu XianDao achieved revenue of 161 million yuan in the first quarter of 2026, with net profit attributable to the parent company of 41.5 million yuan.
财中社·13dRead more ▾